Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.

Halobetasol propionate with tazarotene effective, safe for psoriasis

22 Jul 2018
Psoriasis affecting the upper limb

Halobetasol propionate plus tazarotene (HP/TAZ) significantly reduces the clinical severity of psoriasis with minimal adverse side effects, a recent study has shown.

The present analysis included data from two randomized, double-blind, multicentre, controlled phase 3 studies, where 418 psoriasis patients (65.1 percent male) were randomly assigned 2:1 to receive HP/TAZ lotion or vehicle control once daily for 8 weeks. The study outcomes included treatment success and safety.

At week 8, 35.8 percent (study 1) and 45.3 percent (study 2) of the participants who received HP/TAZ achieved the primary efficacy outcome of at least a 2-grade improvement in Investigator’s Global Assessment score from baseline. This was significantly higher than in the vehicle control groups (7.0 and 12.5 percent, respectively; p<0.001 for both).

Similarly, at the same time point in study 1 and study 2, significantly more participants in the HP/TAZ vs vehicle control group showed improvements in erythema (44.2 percent and 49.6 percent vs 10.0 percent and 18.7 percent) and plaque elevation (59.3 percent and 59.7 percent vs 17.9 percent and 21.3 percent; p<0.001 for all).

In terms of safety, adverse events were more common in participants who received the HP/TAZ lotion than in those who received the control (35.9 percent vs 21.4 percent). Majority of the adverse events (AEs) were mild or moderate in severity (85.6 percent); only three serious AEs were reported, none of which were related to the HP/TAZ lotion,

The most common treatment-related AEs were contact dermatitis, pruritus and pain the application site.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.